Singapore - ASX-listed, cancer diagnostics company, Sienna, has emerging cancer diagnostics in sight as it embarks on M&...
Multiple myeloma patients from Australia will have world-first access to a new first-in-class drug developed to treat th...
A group of researchers from the University of Queensland, Australia has developed a new method that will enable quick an...
Singapore – BlackBerry Limited announced it has become a HIMSS Analytics Certified Consultant to help address the ...
Singapore – Osprey Medical announced that its DyeVert Plus Contrast Reduction System was awarded a group purchasin...
Health Care Originals (HCO) announces its strategic alliance with Healthport. HCO is a leading manufacturer of medical w...
Medical technology company Admedus has appointed former KPMG partner Matthew McDonnell as its interim CFO. With ov...
Leading Australian pharmaceutical firm Phebra has announced the expansion of its international operations, with the esta...
Immuron Limited, an Australian-based microbiome biopharmaceutical company focused on developing and commercializing oral...
Bionic Vision Technologies Pty Ltd (BVT) announced medical researchers had successfully restored a sense of vision ...
Singapore – Elsevier, the information analytics business specializing in science and health, and HIMSS Asia Pacifi...
UK based Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine ...
Singapore - The AusBiotech 2018 annual national three-day conference concluded in Brisbane after attracting over 1,000 d...
Singapore - The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards were announced at the AusBiot...
Singapore - Novotech the largest Asia-Pacific-based CRO has acquired Australasian specialist CRO Clinical Network Servic...
A team at Swansea University Medical School has developed a technology that enables the secure storage and sharing of la...
Elo Life Systems Inc. has announced that Mario G. Pennisi joined Elo Life Systems as a Resident Director of its Australi...
Alphamab Oncology has announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody program, the first of ...
